Market closed

RxSight/$RXST

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About RxSight

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Ticker

$RXST

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

Aliso Viejo, United States

Employees

374

Website

www.rxsight.com

RxSight Metrics

BasicAdvanced

$1.2B

-

-$0.81

1.19 -

Price and volume

Market cap

$1.2B

Beta

1.19

52-week high

$66.54

52-week low

$26.29

Average daily volume

806K

Financial strength

Current ratio

12.668

Quick ratio

11.595

Long term debt to equity

3.812

Total debt to equity

4.077

Interest coverage (TTM)

-1,954.10%

Management effectiveness

Return on assets (TTM)

-9.92%

Return on equity (TTM)

-13.99%

Valuation

Price to revenue (TTM)

9.044

Price to book

4.46

Price to tangible book (TTM)

4.46

Price to free cash flow (TTM)

-42.704

Growth

Revenue change (TTM)

67.52%

Earnings per share change (TTM)

-52.08%

3-year revenue growth (CAGR)

88.74%

3-year earnings per share growth (CAGR)

-28.57%

What the Analysts think about RxSight

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for RxSight stock.

RxSight Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

RxSight Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

RxSight News

AllArticlesVideos

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

GlobeNewsWire·3 days ago

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

GlobeNewsWire·2 weeks ago

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye

Seeking Alpha·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RXST

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for RxSight stock?

RxSight (RXST) has a market cap of $1.2B as of January 15, 2025.

What is the P/E ratio for RxSight stock?

The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of January 15, 2025.

Does RxSight stock pay dividends?

No, RxSight (RXST) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next RxSight dividend payment date?

RxSight (RXST) stock does not pay dividends to its shareholders.

What is the beta indicator for RxSight?

RxSight (RXST) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.